{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:21:00Z","timestamp":1793262060978,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jhep.2021.10.026","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T11:17:17Z","timestamp":1636543037000},"page":"577-587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study"],"prefix":"10.1016","volume":"76","author":[{"given":"Barbara K.","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Feillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7575-4443","authenticated-orcid":false,"given":"Katryn N.","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Marulkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8047-5011","authenticated-orcid":false,"given":"Manisha","family":"Balwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.10.026_bib1","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Lysosomal acid lipase deficiency: the continuous spectra of disease variants","author":"Grabowski","year":"2019"},{"key":"10.1016\/j.jhep.2021.10.026_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2014.04.003","article-title":"Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction","volume":"235","author":"Reiner","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jhep.2021.10.026_bib3","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMe1509055","article-title":"Lysosomal acid lipase deficiency - a new therapy for a genetic lipid disease","volume":"373","author":"Rader","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.10.026_bib4","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jhep.2013.02.014","article-title":"Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease","volume":"58","author":"Bernstein","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.026_bib5","series-title":"Kanuma\u00ae (sebelipase alfa) [package insert]","year":"2015"},{"key":"10.1016\/j.jhep.2021.10.026_bib6","series-title":"Kanuma\u00ae (sebelipase alfa) [summary of product characteristics]","year":"2015"},{"key":"10.1016\/j.jhep.2021.10.026_bib7","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","article-title":"A\u00a0phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency","volume":"373","author":"Burton","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.10.026_bib8","series-title":"World Congress of Pediatric Gastroenterology, Hepatology and Nutrition; October 5-8","article-title":"Long-term benefit of sebelipase alfa over 52 weeks in children and adults with lysosomal acid lipase deficiency (ARISE) [poster 158]","author":"Furuya","year":"2016"},{"key":"10.1016\/j.jhep.2021.10.026_bib9","series-title":"Annual Meeting of the American Association for the Study of Liver Diseases; November 11-15","article-title":"Long-term benefit of sebelipase alfa over 76 weeks in children and adults with lysosomal acid lipase deficiency (ARISE) [poster 564]","author":"Furuya","year":"2016"},{"key":"10.1016\/j.jhep.2021.10.026_bib10","series-title":"Annual Meeting of the American Association for the Study of Liver Diseases; October 20-24","article-title":"Long-term benefit of sebelipase alfa over 100 weeks in children and adults with lysosomal acid lipase deficiency (ARISE study) [poster 809]","author":"Burton","year":"2017"},{"issue":"246","key":"10.1016\/j.jhep.2021.10.026_bib11","first-page":"1","article-title":"2000 CDC Growth Charts for the United States: methods and development","author":"Kuczmarski","year":"2002","journal-title":"Vital Health Stat 11"},{"key":"10.1016\/j.jhep.2021.10.026_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13023-017-0587-3","article-title":"Survival in infants treated with sebelipase alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study","volume":"12","author":"Jones","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jhep.2021.10.026_bib13","first-page":"30","article-title":"Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization","volume":"49","author":"Huffaker","year":"2019","journal-title":"JIMD Rep"},{"key":"10.1016\/j.jhep.2021.10.026_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jacl.2015.03.074","article-title":"Estimation of 10 year Framingham cardiovascular (CV) risk of adults with lysosomal acid lipase (LAL) deficiency [abstract 161]","volume":"9","author":"Shah","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jhep.2021.10.026_bib15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jacl.2018.02.020","article-title":"Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency","volume":"12","author":"Wilson","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"issue":"1 suppl","key":"10.1016\/j.jhep.2021.10.026_bib16","first-page":"1169A","article-title":"Efficacy and safety of sebelipase alfa over 144 weeks in a diverse population of children and adults with lysosomal acid lipase deficiency [abstract 1958]","volume":"70","author":"Burton","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.026_bib17","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/liv.14603","article-title":"Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study","volume":"40","author":"Malinov\u00e1","year":"2020","journal-title":"Liver Int"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:44:09Z","timestamp":1759175049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821021711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0168827821021711"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.10.026","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}